Is Azenta, Inc. overvalued or undervalued?

As of 9 August 2022, the valuation grade for Azenta, Inc. moved from very expensive to risky, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios highlight this concern: the price-to-book value stands at 1.00, the EV to EBITDA ratio is at 38.38, and the ROCE is a negative -2.84%. These figures suggest that the company's financial performance is not aligned with its market valuation.
In comparison to its peers, Azenta, Inc. shows a stark contrast; for instance, Guardant Health, Inc. has an EV to EBITDA of -15.94, while Amedisys, Inc. has a P/E ratio of 20.53. This indicates that Azenta is not only underperforming relative to its industry but also facing challenges in generating profits, as evidenced by its loss-making status reflected in the NA P/E ratio. The company's recent stock performance has also lagged significantly behind the S&P 500, with a year-to-date return of -41.74% compared to the S&P 500's 2.44%.